电邮这篇文章 Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma
- 作者: Mitina TA1, Golenkov AK1
-
隶属关系:
- Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского
- 期: 卷 80, 编号 7 (2008)
- 页面: 48-50
- 栏目: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/30204
- ID: 30204
如何引用文章
全文:
详细
Aim. To assess efficacy of velcade monotherapy in patients with resistent and recurrent multiple myeloma (MM). Material and methods. Velcade was given to 29 patients (11 males and 18 females at the age 41-73 years) with resistant and recurrent MM of stage 3. A standard scheme was used - 1.3 mg/m2 iv jet on day 1, 4, 8 and 11. The cycle was 21 days, a total of 6 cycles. All the patients were examined immunochemically for serum and urine Pig. An antitumor effect was studied. Results. After, on the average, 3 courses of velcade therapy Pig reduction was 31.3%. The response was complete (CR) in 3.4%, partial (PR) in 44.6%, minor response (MR) in 17% and no response (NR) in 35% patients. After 6 cycles of velcade monotherapy given to 23 patients Pig reduction was 59%. CR, PR, MR, NR were seen in 2 (8.7%), 11 (47.8%), 4 (17.4%), 6 (26.1%) patients, respectively. Progression occurred in 8.7%. After 3 cycles of velcade therapy in 29 patients an objective response occurred in 48%, after 6 cycles it increased to 56.5%. The group with poor respose (MR+NR) reduced from 52 (after 3 cycles) to 43.5% (after 6 cycles) patients. Cumulative toxicity of velcade 10 days after the end of cycles 3 and 6 was absent.
关键词
作者简介
T Mitina
Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского
A Golenkov
Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского
参考
- Niesvizky R., Richardson Р. G., Sonnejeld P. et al. Relationship between quality of response to bortezomib and clinical benefit in multiple myeloma in the APEX and Summit studies. Blood 2006; 108 (11): 1007a.
- Richardson P. G., Britmberg H., Jagannath S. et al. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib. Summit and Crest study group. Hematol. J. 2004; 5 (suppl. 2): S129, abstr. 368.
- Richardson P. G., Sonneveld P., Schuster M. W. et al. Bortezomib to demonstrate superior efficacy compared with high dose dexametasone in relapsed multiple myeloma: updated results in the APEX trial. Blood 2005; 106: 715a.
- Richardson P. G., Sonneveld P., Schuster M. W. et al. Bortezomib demonstrates superior survival compared with high-dose dexametasone and higher response rates after extended follow-up in the APEX trial in relapsed multiple myeloma. Haematologica 2006; 91 (suppl. 1): 84.
- Jakubowiak A. J., Brackett L., Kendall T. et al. Combination therapy with velcade, doxil and dexametasone (VDD) for patient with relaps/refractory multiple myeloma. Blood 2005; 106 (11): 378.
- Jagannath S., Richardson P. G., Barlogie B. et al. Bortezomib in combination with dexametasone for the treatment of patients with relapsed and for refractory multiple myeloma. Hematol. J. 2004; 5 (suppl. 2): 130.
- Orlowski R. Z., Voorhus P. M., Garcia R. A. et al. Phase I Study of the proteosome ingibitor bortezomib and pegylated liposomal doxorubicin in patient with advanced hematologic malignancies. Hematol. J. 2004; 5 (suppl. 2): 130.
- Prince M., Adena M., Smith D. K., Hertel J. Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review. Haematologica 2006; 91 (suppl. 1): 85.
- Durie B. G. M. Stading and kinetics in multiple myeloma. In: Salmon S. F. (ed). Clinics Haematology: Myeloma and related disorders. Oxford; WB Saunders Company; 1982; vol. 2: 3-18.
- Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoetic stemm cell transplantation. Myeloma Subcommitee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 1998; 102: 1115-1123.
补充文件
